Estimated Conjunctivitis-Related Healthcare Cost Savings With Increased Tralokinumab Use Versus Other Biologics Among Patients With Moderate-Severe Atopic Dermatitis in the United States
Main Article Content
Keywords
conjunctivitis, cost, atopic dermatitis
References
2. Akinlade et al. Br J Dermatol. 2019;181(3):459-473.
3. Stein Gold et al. J of Skin. 2025;9(1):s511.
4. Reich et al. Br J Dermatol. 2025;ljaf309.
5. Wollenberg et al. Br J Dermatol. 2022;186(3):453-465.
6. US Census Bureau, "U.S. and world population clock"
7. US Census Bureau, "Annual Estimates of the Resident Population by Single Year of Age and Sex for the United States: April 1, 2020 to July 1, 2024 (NCEST2024-SYASEXN)", released June 2025.
8. National Center for Health Statistics. National Health Interview Survey, 2021. Public-use data file and documentation. https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm. 2022.
9. Silverberg et al. Dermatitis. 2014;25(3):107-14.
10. Chiesa Fuxench et al. J Invest Dermatol. 2019;139(3):583-590.
11. Boytsov et al. J Dermatolog Treat. 2022;33(3):1707-1717.
12. Pepose et al. Clin Ophthalmol. 2020;14:377-387.
13. Zimmermann et al. J Drugs Dermatol. 2018;17(7):750-756.
14. Schneider et al. J Manag Care Med. 2014;17(1):78-83.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.